Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Targeted oncology

• Publication date

  2016-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s11523-015-0391-8PMID 26566946PMCID PMC4873478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.

  2015cited by this paper
• A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells

  2014cited by this paper
• Identification and characterization of a novel scFv recognizing human and mouse CD133

  2013cited by this paper
• Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

  2013cited by this paper
• Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.

  2013cited by this paper
• Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells

  2013cited by this paper
• Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

  2012cited by this paper
• Immunotoxin targeting CD133+ breast carcinoma cells

  2012cited by this paper
• Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system

  2012cited by this paper
• T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16

  2012cited by this paper
• Targeting Tumor-Initiating Cancer Cells with dCD133KDEL Shows Impressive Tumor Reductions in a Xenotransplant Model of Human Head and Neck Cancer

  2011cited by this paper
• Pancreatic Cancer Cells Resistant to Chemoradiotherapy Rich in “Stem-Cell-Like” Tumor Cells

  2011cited by this paper
• Innate or Adaptive Immunity? The Example of Natural Killer Cells

  2011cited by this paper
• Therapeutic implications of colon cancer stem cells.

  2010cited by this paper
• Identification of a novel monoclonal antibody recognizing CD133.

  2010cited by this paper
• Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16

  2010cited by this paper
• Novel conjugates of single‐chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

  2010cited by this paper
• Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics

  2008cited by this paper
• Ultrastructural characterization of CD133+ stem cells bound to superparamagnetic nanoparticles: possible biotechnological applications

  2008cited by this paper
• CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

  2008cited by this paper
• Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma.

  2007cited by this paper
• Cancer Stem Cells

  2007cited by this paper
• Cancer stem cells.

  2006cited by this paper
• Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

  2006cited by this paper
• BiTEs: bispecific antibody constructs with unique anti-tumor activity.

  2005cited by this paper
• TL1A Synergizes with IL-12 and IL-18 to Enhance IFN-γ Production in Human T Cells and NK Cells1

  2004cited by this paper
• TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells.

  2004cited by this paper
• Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors.

  2000cited by this paper
• The Human AC133 Hematopoietic Stem Cell Antigen Is also Expressed in Epithelial Cells and Targeted to Plasma Membrane Protrusions*

  2000cited by this paper
• Direct isolation of human central nervous system stem cells.

  2000cited by this paper
• Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.

  1999cited by this paper
• AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family?

  1998cited by this paper
• AC133, a novel marker for human hematopoietic stem and progenitor cells.

  1997cited by this paper
• Caco‐2 cells cultured in serum‐free medium as a model for the study of enterocytic differentiation in vitro

  1991cited by this paper
• One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

  1977cited by this paper
• Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

  1968cited by this paper

• Prognostic associations of systemic inflammation response index (SIRI) in patients with head and neck cancer: a systematic review and meta-analysis.

  2026cites this paper
• Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities

  2025cites this paper
• Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities

  2025cites this paper
• Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease

  2025cites this paper
• Beyond CAR-T: Engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy.

  2025cites this paper
• Engineered natural killer cells for cancer therapy.

  2025cites this paper
• Strategies for the Generation of Bispecific Antibodies

  2025cites this paper
• Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy

  2025cites this paper
• High systemic inflammation response index (SIRI) level as a prognostic factor for colorectal cancer patients after curative surgery: a single-center retrospective analysis

  2025cites this paper
• Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment

  2025cites this paper
• Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways

  2024cites this paper
• Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases

  2024cites this paper
• Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment

  2024cites this paper
• Single-Stranded Variable Fragment Gene Libraries Built for Phage Display: An Updated Review of Design, Selection and Application

  2024cites this paper
• Engineered Cellular Therapies for the Treatment of Thoracic Cancers

  2024cites this paper
• Pharmacological Agents Targeting Drug-Tolerant Persister Cells in Cancer.

  2024cites this paper
• Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.

  2023cites this paper
• Update on immune‐based therapy strategies targeting cancer stem cells

  2023cites this paper
• Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy

  2023cites this paper
• Harnessing Natural Killer Cells for Lung Cancer Therapy.

  2023cites this paper
• Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas

  2023cites this paper
• A targetable pathway to eliminate TRA-1-60+/TRA-1-81+ chemoresistant cancer cells

  2023cites this paper
• Cell Therapy as Target Therapy against Colon Cancer Stem Cells

  2023influential citation
• Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody

  2023cites this paper
• Mapping the interplay between NK cells and HIV: therapeutic implications

  2023cites this paper
• Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers.

  2022cites this paper
• Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy

  2022cites this paper
• Targeting natural killer cells in cancer immunotherapy

  2022cites this paper
• Natural killer cells in antitumour adoptive cell immunotherapy

  2022cites this paper
• The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics

  2022cites this paper
• Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment.

  2022cites this paper
• Bispecific antibodies for immune cell retargeting against cancer

  2022cites this paper
• Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22

  2022cites this paper
• Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy

  2022cites this paper
• Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody

  2022cites this paper
• Employing CRISPR-Cas9 to Generate CD133 Synthetic Lethal Melanoma Stem Cells

  2022cites this paper
• The War Is on: The Immune System against Glioblastoma—How Can NK Cells Drive This Battle?

  2022cites this paper
• Biology and Clinical Evaluation of T/NK Cell Engagers

  2022cites this paper
• Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy.

  2022cites this paper
• Multiplexed engineering and precision gene editing in cellular immunotherapy

  2022cites this paper
• Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors

  2021cites this paper
• Novel Immune Engagers and Cellular Therapies for Metastatic Castration-Resistant Prostate Cancer: Do we take a BiTe or ride BiKEs, TriKEs, and CARs?

  2021cites this paper
• A comprehensive comparison between camelid nanobodies and single chain variable fragments

  2021cites this paper
• Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor

  2021cites this paper
• Immunometabolic targeting of NK cells to solid tumors

  2021cites this paper
• Antibody fragment and targeted colorectal cancer therapy: A global systematic review.

  2021cites this paper
• Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy

  2021cites this paper
• CD133 Promotes Resistance to Trametinib in Melanoma Stem Cells by Activating an AKT / BCL-2 Survival Pathway

  2021cites this paper
• Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments

  2021cites this paper
• The promise of bispecific antibodies: Clinical applications and challenges.

  2021cites this paper
• Portrait of Cancer Stem Cells on Colorectal Cancer: Molecular Biomarkers, Signaling Pathways and miRNAome

  2021cites this paper
• Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs

  2021cites this paper
• Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma

  2021cites this paper
• Natural Killer Cells in Post-Transplant Lymphoproliferative Disorders

  2021cites this paper
• Targeting Therapies for Cancer Stem Cells

  2020cites this paper
• Harnessing natural killer cells for the treatment of ovarian cancer.

  2020cites this paper
• Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics

  2020cites this paper
• The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma.

  2020cites this paper
• MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine.

  2020cites this paper
• CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma

  2020cites this paper
• Development and clinical application of bispecific antibody in the treatment of colorectal cancer

  2020cites this paper
• Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

  2020cites this paper
• Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in E. Coli for Cancer Immunotherapy.

  2020cites this paper
• NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo

  2020cites this paper
• Toward Drug-Like Multispecific Antibodies by Design

  2020cites this paper
• Cancer Stem Cells: New Horizons in Cancer Therapies

  2020cites this paper
• Natural Killer Cells in Immunotherapy: Are We Nearly There?

  2020cites this paper
• Recent developments in antibody derivatives against colorectal cancer; A review.

  2020cites this paper
• The role of natural killer cell in gastrointestinal cancer: killer or helper

  2020cites this paper
• The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer

  2020cites this paper
• An optimal control approach for enhancing natural killer cells' secretion of cytolytic molecules

  2020cites this paper
• Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

  2019cites this paper
• Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors

  2019cites this paper
• Exploiting NK Cell Surveillance Pathways for Cancer Therapy

  2019cites this paper
• Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies

  2018cites this paper
• Tumor immunotherapy: New aspects of natural killer cells.

  2018cites this paper
• The role of CD133 in cancer: a concise review

  2018cites this paper
• Natural Killer Cells: What Have We Learned?

  2018cites this paper
• Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases

  2018cites this paper
• Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials

  2018cites this paper
• Neuroblastoma Origin and Therapeutic Targets for Immunotherapy

  2018cites this paper
• Natural killer cell–based immunotherapy: From transplantation toward targeting cancer stem cells

  2018cites this paper
• Current strategies exploiting NK‐cell therapy to treat haematologic malignancies

  2018cites this paper
• Immobilization of antibodies on cardiovascular stents

  2018cites this paper
• Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review

  2017cites this paper
• Colorectal Cancer Immunotherapy: Current State and Prospects (Review)

  2017cites this paper
• NK cell-based immunotherapy for cancer.

  2017cites this paper
• Novel biotechnology approaches in colorectal cancer diagnosis and therapy

  2017cites this paper
• Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity

  2017cites this paper
• Tumor location impacts immune response in mouse models of colon cancer

  2017cites this paper
• Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy

  2017cites this paper
• Role of Natural Killer Cells in HIV-Associated Malignancies

  2017cites this paper
• Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.

  2017cites this paper
• The making of bispecific antibodies

  2017cites this paper
• Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy

  2017cites this paper
• NK cell education and adhesion molecules : implications for immunotherapy

  2016cites this paper
• Investigating functions of tumor-infiltrating natural killer cells in genetically-engineered mouse models of non-small cell lung cancer

  2016cites this paper
• Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.

  2016cites this paper
• Bispecific antibodies in cancer immunotherapy

  2016cites this paper
• Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker

  2016cites this paper